Werewolf Therapeutics (HOWL) Cash from Financing Activities (2020 - 2025)

Werewolf Therapeutics has reported Cash from Financing Activities for 6 years, with the latest figure at $2.4 million in Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $2.4 million, down 7.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.0 million (down 53.91% YoY), and the FY2025 annual result was $6.0 million, down 53.91% from the prior year.
• Cash from Financing Activities retreated to $2.4 million in Q4 2025, from $3.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $110.2 million in Q2 2021 and troughed at -$9.7 million in Q2 2024.
• A 5-year average of $10.7 million and a median of $1.3 million in 2022 frame the typical range for Cash from Financing Activities.
• The widest annual swing landed in 2024, when Cash from Financing Activities slumped 1504.62%; it then surged 54666.67% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $38000.0 in 2021, then jumped by 3205.26% to $1.3 million in 2022, then jumped by 622.37% to $9.1 million in 2023, then tumbled by 71.93% to $2.5 million in 2024, then declined by 7.11% to $2.4 million in 2025.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $2.4 million in Q4 2025, $3.3 million in Q3 2025, and $388000.0 in Q2 2025.